Protagonist Therapeutics financials
$140.97−1.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M | $28.6M | $231.0K | $30.9M | $20.1M | — |
| Gross profit | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M | $28.6M | $231.0K | $30.9M | $20.1M | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$158.1M | $252.8M | -$93.7M | -$131.4M | -$125.8M | -$64.5M | -$80.5M | -$42.3M | -$37.9M | -$32.7M |
| Net income | -$130.1M | $275.2M | -$79.0M | -$127.4M | -$125.6M | -$66.2M | -$77.2M | -$38.9M | -$37.0M | -$37.7M |
| Net margin | −282.8% | 63.3% | −131.6% | −479.3% | −458.9% | −231.1% | −33414.3% | −125.9% | −184.2% | — |
| Diluted EPS | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 | $-1.92 | $-2.98 | $-1.74 | $-2.09 | $-5.80 |
| EBITDA | -$156.8M | $253.7M | -$92.7M | -$130.3M | -$123.1M | -$63.5M | -$80.4M | -$41.5M | -$36.8M | -$32.2M |
| Operating cash flow | $57.7M | $184.2M | -$70.2M | -$108.1M | -$107.9M | -$72.5M | -$41.5M | -$49.9M | $3.9M | -$30.0M |
| Free cash flow | $56.1M | $182.8M | -$70.8M | -$108.9M | -$109.0M | -$73.0M | -$42.5M | -$50.4M | $3.2M | -$30.3M |
| Diluted shares | 63.6M | 65.1M | 56.8M | 49.0M | 46.3M | 34.4M | 25.9M | 22.4M | 17.7M | 6.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $128.4M | $97.2M | $186.7M | $125.7M | $123.7M | $117.4M |
| Short-term investments | $439.0M | $321.7M | $154.9M | $111.6M | $203.2M | $188.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $668.2M | $744.7M | $358.0M | $247.9M | $347.7M | $324.5M |
| Total liabilities | $53.5M | $69.4M | $21.3M | $32.3M | $47.7M | $44.9M |
| Shareholders' equity | $614.7M | $675.3M | $336.7M | $215.6M | $300.0M | $279.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology